Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1

Conditions

Breast Neoplasms 9Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Neoplasms 2Fractures, Bone 2Prostatic Intraepithelial Neoplasia 1Precancerous Conditions 1Osteoporosis 1Neoplasms 1Bone Diseases, Metabolic 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Toremifene × Clear all
NCT00106691 2023-06-12

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

GTx

Phase 3 Completed
1,589 enrolled 16 charts
GenitourinaryOther neoplasm

Neoplasms, Precancerous Conditions, Prostatic Intraepithelial Neoplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡